Streck, a member of Bio Nebraska, announced today a Series B investment in Ceres Nanosciences to be used to accelerate the development and commercialization of both diagnostic and research use products utilizing the Ceres Nanotrap® technology platform.
Announcement from Streck
Streck announced today a Series B investment in Ceres Nanosciences (Ceres). The funds from this investment will be used to accelerate the development and commercialization of both diagnostic and research use products utilizing Ceres’ Nanotrap® technology platform.
“Streck has a deep presence in and knowledge of the diagnostics industry and shares our commitment to building long-term relationships with partners and customers,” said Ceres CEO Ross Dunlap. “We are thrilled to have Streck’s support and guidance in this next, exciting phase of our growth.”
This investment builds on the pre-existing partnership between Ceres and Streck, which has produced the Streck® Viral Extraction Kit, powered by Nanotrap technology, and a global distribution agreement covering Nanotrap particles for virus capture and concentration from wastewater samples.
“Ceres has a fantastic reputation for delivering innovative, high-quality products,” said Matthew Kreifels, Vice President of Sales. “We look forward to the positive impacts this partnership will have and working closely with their team to maximize the company’s impacts in the public health and diagnostics arenas.”
Streck will join Series A investor GreyBird Ventures on Ceres’ Board of Directors.